Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Omega Therapeutics, Inc.OMGA · Entity 83618 | Chief Scientific Officer | February 07, 2024 | February 09, 2024 |
| Stoke Therapeutics, Inc.STOK · Entity 1723 | Chief Scientific Officer | July 15, 2026 | July 17, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Omega Therapeutics, Inc.
Report date February 07, 2024 · Filed February 09, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.59 · Expires 2034-02-06 | Direct | 125,000 |
Reported balance
After 2024-02-07 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2024-02-07 · Grant · Acquired 125,000 · Balance 125,000 F1: The option vests and becomes exercisable with respect to 25% of the underlying shares on February 7, 2025 and in twelve (12) equal quarterly installments thereafter such that the option will become fully vested and exercisable on February 7, 2028, subject to the Reporting Person's continued service to the Issuer through each such vesting date. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.59 · Expires 2034-02-06 | Direct | 75,000 |
Reported balance
After 2024-02-07 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2024-02-07 · Grant · Acquired 75,000 · Balance 75,000 F2: The option vests and becomes exercisable in three equal installments on each of October 7, 2024, June 7, 2025 and February 7, 2026, subject to the Reporting Person's continued service to the Issuer through each such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The option vests and becomes exercisable with respect to 25% of the underlying shares on February 7, 2025 and in twelve (12) equal quarterly installments thereafter such that the option will become fully vested and exercisable on February 7, 2028, subject to the Reporting Person's continued service to the Issuer through each such vesting date.
F2: The option vests and becomes exercisable in three equal installments on each of October 7, 2024, June 7, 2025 and February 7, 2026, subject to the Reporting Person's continued service to the Issuer through each such vesting date.
Stoke Therapeutics, Inc.
Report date July 15, 2026 · Filed July 17, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $29.91 · Expires 2036-07-14 | Direct | 225,000 |
Reported balance
After 2026-07-15 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-07-15 · Grant · Acquired 225,000 · Balance 225,000 F1: The stock option vests as to 1/4 of the total award on July 15, 2027, and as to 1/48 of the total award monthly thereafter, subject to the reporting person's continued service to the Issuer on each vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The stock option vests as to 1/4 of the total award on July 15, 2027, and as to 1/48 of the total award monthly thereafter, subject to the reporting person's continued service to the Issuer on each vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 15, 2026 Filed Jul 17, 2026 20:35 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | GrantStock Option (Right to Buy) · Derivative | 225,000 | $0.00 Strike: $29.91 | $0.00 |
DisclosureSEC source: 0001858760-26-000008 · form4-07172026_080754.xml · derivative · entry 1 McCauley Thomas · CIK 0001858760 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 225,000 Underlying: Common Stock · 225,000 shares Expires 2036-07-14 F1 · derivative.exercise_date: The stock option vests as to 1/4 of the total award on July 15, 2027, and as to 1/48 of the total award monthly thereafter, subject to the reporting person's continued service to the Issuer on each vesting date. Read SEC document |
| February 07, 2024 Filed Feb 9, 2024 22:14 UTC | Omega Therapeutics, Inc. OMGA · Entity 83618 | GrantStock Option (Right to Buy) · Derivative | 75,000 | $0.00 Strike: $3.59 | $0.00 |
DisclosureSEC source: 0000950170-24-013378 · ownership.xml · derivative · entry 2 McCauley Thomas · CIK 0001858760 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Stock · 75,000 shares Expires 2034-02-06 F2 · derivative.exercise_date: The option vests and becomes exercisable in three equal installments on each of October 7, 2024, June 7, 2025 and February 7, 2026, subject to the Reporting Person's continued service to the Issuer through each such vesting date. Read SEC document |
| February 07, 2024 Filed Feb 9, 2024 22:14 UTC | Omega Therapeutics, Inc. OMGA · Entity 83618 | GrantStock Option (Right to Buy) · Derivative | 125,000 | $0.00 Strike: $3.59 | $0.00 |
DisclosureSEC source: 0000950170-24-013378 · ownership.xml · derivative · entry 1 McCauley Thomas · CIK 0001858760 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 125,000 Underlying: Common Stock · 125,000 shares Expires 2034-02-06 F1 · derivative.exercise_date: The option vests and becomes exercisable with respect to 25% of the underlying shares on February 7, 2025 and in twelve (12) equal quarterly installments thereafter such that the option will become fully vested and exercisable on February 7, 2028, subject to the Reporting Person's continued service to the Issuer through each such vesting date. Read SEC document |
| February 28, 2023 Filed Mar 2, 2023 21:05 UTC | Omega Therapeutics, Inc. OMGA · Entity 83618 | GrantOption (Right to Buy) · Derivative | 55,000 | $0.00 Strike: $6.46 | $0.00 |
DisclosureSEC source: 0000899243-23-006725 · doc4.xml · derivative · entry 1 McCauley Thomas · CIK 0001858760 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,000 Underlying: Common Stock · 55,000 shares Expires 2033-02-27 F1 · derivative.exercise_date: The options vest and become exercisable with respect to 25% of the underlying shares on February 28, 2024 and in equal quarterly installments thereafter such that the option will become fully vested and exercisable on February 28, 2027, subject to the Reporting Person's continued service to the Issuer through each vesting date. Read SEC document |
| October 27, 2022 Filed Oct 28, 2022 22:40 UTC | Omega Therapeutics, Inc. OMGA · Entity 83618 | GrantOption (Right to Buy) · Derivative | 55,000 | $0.00 Strike: $5.27 | $0.00 |
DisclosureSEC source: 0000899243-22-034470 · doc4.xml · derivative · entry 1 McCauley Thomas · CIK 0001858760 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,000 Underlying: Common Stock · 55,000 shares Expires 2032-10-26 F1 · derivative.exercise_date: The options vest and become exercisable as to 25% of the underlying shares on October 27, 2023 and as to 6.25% of the underlying shares upon the Reporting Person's completion of each three full months of continued service to the Issuer thereafter, such that the option will be fully vested and exercisable on October 27, 2026. Read SEC document |
| March 09, 2022 Filed Mar 11, 2022 21:05 UTC | Omega Therapeutics, Inc. OMGA · Entity 83618 | GrantOption (Right to Buy) · Derivative | 110,000 | $0.00 Strike: $10.34 | $0.00 |
DisclosureSEC source: 0000899243-22-010692 · doc4.xml · derivative · entry 1 McCauley Thomas · CIK 0001858760 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 110,000 Underlying: Common Stock · 110,000 shares Expires 2032-03-08 F1 · derivative.exercise_date: The options vest and become exercisable with respect to 25% of the underlying shares on March 9, 2023 and in equal quarterly installments thereafter such that the option will become fully vested and exercisable on March 9, 2026, subject to the Reporting Person's continued service to the Issuer through each vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.